| Controlled substance | Schedule |
|-----------------------------------------------------|----------|
| Dextropropoxyphene, bulk (non-dosage forms) (9273). | II |
| Morphine (9300) Thebaine (9333) | |
| Levo-alphacetylmethadol (9648) Oxymorphone (9652) | II II |
| Noroxymorphone (9668) | ii |
| Racemethorphan (9732)Alfentanil (9737) | |
| Remifentanil (9739) | ii |
| Sufentanil (9740) | |
| Tapentadol (9780) Fentanyl (9801) | II II |
| Tontanyi (0001) | " |

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Dated: August 19, 2014.

Joseph T. Rannazzisi,

 $Deputy \ Assistant \ Administrator.$

[FR Doc. 2014-20201 Filed 8-25-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: PCAS-Nanosyn, LLC

ACTION: Notice of registration.

SUMMARY: PCAS-Nanosyn, LLC applied to be registered as a manufacturer of certain basic classes of narcotic and non-narcotic controlled substances. The DEA grants PCAS-Nanosyn, LLC registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the Federal Register on April 30, 2014, 79 FR 24452, PCAS-Nanosyn, LLC, 3331–B Industrial Drive, Santa Rosa, California 95403, applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. No comments or objections have been received.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of PCAS-Nanosyn, LLC to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and

testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of narcotic and non-narcotic controlled substances listed:

| Controlled substance | Schedule |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Amphetamine (1100) Methamphetamine (1105) Methylphenidate (1724) Phencyclidine (7471) Codeine (9050) Oxycodone (9143) Hydromorphone (9150) Hydrocodone (9193) Methadone (9250) Morphine (9300) Oripavine (9330) Oxymorphone (9652) Fentanyl (9801) | |
| | |

The company is a contract manufacturer. At the request of the company's customers, it manufactures derivatives of controlled substances only in bulk form.

Dated: August 19, 2014.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2014–20196 Filed 8–25–14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: Patheon Pharmaceuticals, Inc.

ACTION: Notice of registration.

SUMMARY: Patheon Pharmaceuticals, Inc., applied to be registered as a manufacturer of a certain basic class of controlled substance. The DEA grants Patheon Pharmaceuticals, Inc., registration as a manufacturer of the controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the **Federal Register** on April 28, 2014, 79 FR 23373, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237, applied to be registered as a manufacturer of a certain basic class of non-narcotic controlled substance. No

comments or objections have been received.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Patheon Pharmaceuticals, Inc., to manufacture the basic class of this controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I.

The company plans to manufacture the listed controlled substance for distribution to its customers.

Dated: August 19, 2014.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2014-20198 Filed 8-25-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF LABOR

Office of the Secretary

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Fire Protection in Shipyard Employment Standard

ACTION: Notice.

SUMMARY: The Department of Labor (DOL) is submitting the Occupational Safety and Health Administration (OSHA) sponsored information collection request (ICR) titled, "Fire Protection in Shipyard Employment Standard," to the Office of Management and Budget (OMB) for review and approval for continued use, without change, in accordance with the Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 et seq. Public comments on the ICR are invited.

DATES: The OMB will consider all written comments that agency receives on or before September 25, 2014.

ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely